Furthermore, PD-L1 expression in tumors is positively correlated with the number of tumor-infiltrating lymphocytes 47, indicating that cancer patients with high intratumoral PD-L1 expression are more likely to respond to immune checkpoint therapy. The gene discussed is CD274; the disease is cancer.